Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2011
Progression-free survival ratio as end point for phase II trials in advanced solid tumors
Marc Buyse, Emmanuel Quinaux, Alain Hendlisz, et al.
Clinical Trials (London, England)
|
June 24, 2017
The impact of data errors on the outcome of randomized clinical trials
Marc Buyse, Pierre Squifflet, Elisabeth Coart, et al.
Statistics in Medicine
|
October 23, 2023
Minimization in randomized clinical trials
Elisabeth Coart, Perrine Bamps, Emmanuel Quinaux, et al.
Clinical Colorectal Cancer
|
April 10, 2010
Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1)
Isabelle Baumgaertner, Emmanuel Quinaux, Ahmed Khalil, et al.
BMJ Open
|
March 15, 2013
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials
Silvy Laporte, Pierre Squifflet, Noémie Baroux, et al.
The Lancet. Oncology
|
February 3, 2019
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis
Everardo D Saad, Pierre Squifflet, Tomasz Burzykowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2003
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
Christophe Tournigand, Thierry André, Emmanuel Achille, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2023
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
Christophe Tournigand, Thierry André, Emmanuel Achille, et al.
Hepatology (Baltimore, Md.)
|
October 28, 2003
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C
Frederik Nevens, Tania Roskams, Hans Van Vlierberghe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2007
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1
Thierry André, Emmanuel Quinaux, Christophe Louvet, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2011
Progression-free survival ratio as end point for phase II trials in advanced solid tumors
Marc Buyse, Emmanuel Quinaux, Alain Hendlisz, et al.
Clinical Trials (London, England)
|
June 24, 2017
The impact of data errors on the outcome of randomized clinical trials
Marc Buyse, Pierre Squifflet, Elisabeth Coart, et al.
Statistics in Medicine
|
October 23, 2023
Minimization in randomized clinical trials
Elisabeth Coart, Perrine Bamps, Emmanuel Quinaux, et al.
Clinical Colorectal Cancer
|
April 10, 2010
Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1)
Isabelle Baumgaertner, Emmanuel Quinaux, Ahmed Khalil, et al.
BMJ Open
|
March 15, 2013
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials
Silvy Laporte, Pierre Squifflet, Noémie Baroux, et al.
The Lancet. Oncology
|
February 3, 2019
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis
Everardo D Saad, Pierre Squifflet, Tomasz Burzykowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2003
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study
Christophe Tournigand, Thierry André, Emmanuel Achille, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2023
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
Christophe Tournigand, Thierry André, Emmanuel Achille, et al.
Hepatology (Baltimore, Md.)
|
October 28, 2003
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C
Frederik Nevens, Tania Roskams, Hans Van Vlierberghe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2007
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1
Thierry André, Emmanuel Quinaux, Christophe Louvet, et al.
Page
of 2